Recent developments in cell-based immune therapy for neuroblastoma

Michael R. Verneris; John E. Wagner

doi:10.1007/s11481-007-9065-3

Recent developments in cell-based immune therapy for neuroblastoma

Michael R. Verneris, John E. Wagner

Pediatrics - Blood/Marrow Transplant

Research output: Contribution to journal › Review article › peer-review

9 Scopus citations

Abstract

Neuroblastoma (NB) is a common and aggressive tumor of early childhood. To date, treatment with chemotherapy, surgery, and radiation therapy has resulted in suboptimal outcomes in those with advanced disease. Immune-based treatments hold promise for patients with recurrent or advanced NB. Here, recent preclinical studies and early stage (phase I) clinical trials using cellular therapeutic approaches for NB are reviewed, including studies of natural killer cells, γδ T cells, chimeric receptor expressing T cells, dendritic cells, and allogeneic hematopoietic cell transplant.

Original language	English (US)
Pages (from-to)	134-139
Number of pages	6
Journal	Journal of Neuroimmune Pharmacology
Volume	2
Issue number	2
DOIs	https://doi.org/10.1007/s11481-007-9065-3
State	Published - Jun 2007

Bibliographical note

Funding Information:
This work was supported in part by grants from the Children’s Cancer Research Fund and the Minnesota Medical Foundation. M.R.Verneris(*) . J. E. Wagner Blood and Marrow Transplant Program, Department of Pediatrics, University of Minnesota, Mayo Mail Code 366, 420 Delaware Street, S.E., Minneapolis, MN 55455, USA e-mail: verneris@umn.edu

Keywords

Allogeneic transplantation
Dendritic cells
Gd T cells
Immune therapy
Immunotherapy
NK cells
T cells
Vaccine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access

10.1007/s11481-007-9065-3

OpenUrl availability

Full text

Cite this

@article{49a774c52741471397e60b6a1d893e69,

title = "Recent developments in cell-based immune therapy for neuroblastoma",

abstract = "Neuroblastoma (NB) is a common and aggressive tumor of early childhood. To date, treatment with chemotherapy, surgery, and radiation therapy has resulted in suboptimal outcomes in those with advanced disease. Immune-based treatments hold promise for patients with recurrent or advanced NB. Here, recent preclinical studies and early stage (phase I) clinical trials using cellular therapeutic approaches for NB are reviewed, including studies of natural killer cells, γδ T cells, chimeric receptor expressing T cells, dendritic cells, and allogeneic hematopoietic cell transplant.",

keywords = "Allogeneic transplantation, Dendritic cells, Gd T cells, Immune therapy, Immunotherapy, NK cells, T cells, Vaccine",

author = "Verneris, {Michael R.} and Wagner, {John E.}",

note = "Funding Information: This work was supported in part by grants from the Children{\textquoteright}s Cancer Research Fund and the Minnesota Medical Foundation. M.R.Verneris(*) . J. E. Wagner Blood and Marrow Transplant Program, Department of Pediatrics, University of Minnesota, Mayo Mail Code 366, 420 Delaware Street, S.E., Minneapolis, MN 55455, USA e-mail: verneris@umn.edu",

year = "2007",

month = jun,

doi = "10.1007/s11481-007-9065-3",

language = "English (US)",

volume = "2",

pages = "134--139",

journal = "Journal of Neuroimmune Pharmacology",

issn = "1557-1890",

publisher = "Springer New York",

number = "2",

}

TY - JOUR

T1 - Recent developments in cell-based immune therapy for neuroblastoma

AU - Verneris, Michael R.

AU - Wagner, John E.

N1 - Funding Information: This work was supported in part by grants from the Children’s Cancer Research Fund and the Minnesota Medical Foundation. M.R.Verneris(*) . J. E. Wagner Blood and Marrow Transplant Program, Department of Pediatrics, University of Minnesota, Mayo Mail Code 366, 420 Delaware Street, S.E., Minneapolis, MN 55455, USA e-mail: verneris@umn.edu

PY - 2007/6

Y1 - 2007/6

N2 - Neuroblastoma (NB) is a common and aggressive tumor of early childhood. To date, treatment with chemotherapy, surgery, and radiation therapy has resulted in suboptimal outcomes in those with advanced disease. Immune-based treatments hold promise for patients with recurrent or advanced NB. Here, recent preclinical studies and early stage (phase I) clinical trials using cellular therapeutic approaches for NB are reviewed, including studies of natural killer cells, γδ T cells, chimeric receptor expressing T cells, dendritic cells, and allogeneic hematopoietic cell transplant.

AB - Neuroblastoma (NB) is a common and aggressive tumor of early childhood. To date, treatment with chemotherapy, surgery, and radiation therapy has resulted in suboptimal outcomes in those with advanced disease. Immune-based treatments hold promise for patients with recurrent or advanced NB. Here, recent preclinical studies and early stage (phase I) clinical trials using cellular therapeutic approaches for NB are reviewed, including studies of natural killer cells, γδ T cells, chimeric receptor expressing T cells, dendritic cells, and allogeneic hematopoietic cell transplant.

KW - Allogeneic transplantation

KW - Dendritic cells

KW - Gd T cells

KW - Immune therapy

KW - Immunotherapy

KW - NK cells

KW - T cells

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=34247543464&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247543464&partnerID=8YFLogxK

U2 - 10.1007/s11481-007-9065-3

DO - 10.1007/s11481-007-9065-3

M3 - Review article

C2 - 18040838

AN - SCOPUS:34247543464

SN - 1557-1890

VL - 2

SP - 134

EP - 139

JO - Journal of Neuroimmune Pharmacology

JF - Journal of Neuroimmune Pharmacology

IS - 2

ER -

Recent developments in cell-based immune therapy for neuroblastoma

Abstract

Bibliographical note

Keywords

UN SDGs

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this